Compare drug alternatives

Nurtec ODT® Alternatives

Nurtec ODT®(rimegepant)
Vyepti®(eptinezumab)
Prescription Only
Nurtec ODT is a medication that can be placed under or onto the tongue to treat migraine symptoms in adults. When taken every other day, it can also be used to prevent episodic...
Prescription Only
Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...
Dosage & Administration
Administration
Oral . Learn more.
Intravenous Infusion. Learn more.
Dosing
Acute treatment of migraine: 75 mg as needed. Preventive treatment of episodic migraine: 75 mg every other day. Maximum daily dose: 75 mg.. Learn more.
Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.
Latin Shorthand
Acute treatment of Migraine: 75 mg PRN. Preventive treatment of Episodic Migraine: 75 mg qod.. Learn more.
100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
$200 per infusion administration fee. Learn more.
Assistance Expiration
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
Acute treatment of migraine: the adverse reaction reported in ≥ 1% of patients treated with NURTEC ODT is nausea. Preventive treatment of episodic migraine: adverse reactions reported in ≥ 2% for rimegepant and ≥ 1% higher than placebo are nausea and abdominal pain/dyspepsia.. Learn more.
The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.
CGRP Antagonist. Learn more.
Special Populations
Is NURTEC ODT safe to use during pregnancy?

There are no adequate data on the developmental risk associated with the use of NURTEC ODT in pregnant women. In animal studies, oral administration of rimegepant during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of skeletal variations) at exposures greater than those used clinically and which were associated with maternal toxicity. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated rate of major birth defects (2.2 to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. Women exposed to NURTEC ODT during pregnancy can participate in a pregnancy exposure registry that monitors pregnancy outcomes. Healthcare providers or patients can contact 1-877-366-0324, email nurtecpregnancyregistry@ppd.com, or visit nurtecpregnancyregistry.com for more information.

Can I take NURTEC ODT while breastfeeding?

A lactation study conducted on 12 healthy adult lactating women who were between 2 weeks and 6 months postpartum and were administered a single oral dose of rimegepant 75 mg established a relative infant dose of less than 1% of the maternal weight-adjusted dose and a milk-to-plasma ratio of 0.20. These data support that transfer of rimegepant into breastmilk is low. However, there are no data on the effects of rimegepant on a breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NURTEC ODT and any potential adverse effects on the breastfed infant from NURTEC ODT or from the underlying maternal condition.

Is NURTEC ODT safe for use in children?

Safety and effectiveness in pediatric patients have not been established for NURTEC ODT.

Is NURTEC ODT safe for use in elderly patients?

In pharmacokinetic studies, no clinically significant pharmacokinetic differences were observed between elderly and younger subjects. However, clinical studies of NURTEC ODT did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Do patients with renal impairment need a dosage adjustment of NURTEC ODT?

No, dosage adjustment is not required in patients with mild, moderate, or severe renal impairment. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

What is the recommended dose of NURTEC ODT for patients with severe renal impairment?

The recommended dosage of NURTEC ODT for patients with severe renal impairment (CLcr 15-29 mL/min) is the same as for patients with normal renal function, which is a single dose of 75 mg. However, NURTEC ODT has not been studied in patients with end-stage renal disease and in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

Can patients on dialysis use NURTEC ODT?

NURTEC ODT has not been studied in patients on dialysis. It is advised to avoid the use of NURTEC ODT in patients with end-stage renal disease (CLcr < 15 mL/min).

Is it safe to use VYEPTI during pregnancy?

There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy.

Are there any risks to the fetus if the mother receives VYEPTI?

Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively.

Is it safe to breastfeed while using VYEPTI?

There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding.

Is VYEPTI safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients.

Is VYEPTI safe for use in geriatric patients?

Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.